Prevention of Hepatocellular Carcinoma in Chronic Viral Hepatitis B and C Infection

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Jan 1

PMID 24379612

Citations 16

Authors

Tao Lu

Wai-Kay Seto

Ran-Xu Zhu

Ching-Lung Lai

Man-Fung Yuen

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer.

Citing Articles

Hepatitis B vaccination status and knowledge, attitude, and practice towards Hepatitis B virus among medical sciences students: A cross-sectional study.

Naqid I, Mosa A, Ibrahim S, Ibrahim N, Hussein N PLoS One. 2023; 18(11):e0293822.

PMID: 37930973 PMC: 10627443. DOI: 10.1371/journal.pone.0293822.

A framework for identification and classification of liver diseases based on machine learning algorithms.

Ding H, Fawad M, Xu X, Hu B Front Oncol. 2022; 12:1048348.

PMID: 36313630 PMC: 9614094. DOI: 10.3389/fonc.2022.1048348.

LncRNA RSU1P2-microRNA let-7a-Testis-Expressed Protein 10 axis modulates tumorigenesis and cancer stem cell-like properties in liver cancer.

Liang J, Xu Q, Gu S Bioengineered. 2022; 13(2):4285-4300.

PMID: 35156514 PMC: 8974045. DOI: 10.1080/21655979.2022.2031394.

MicroRNA-135a expression is upregulated in hepatocellular carcinoma and targets long non-coding RNA TONSL-AS1 to suppress cell proliferation.

Deng X, Cheng J, Zhan N, Chen J, Zhan Y, Ni Y Oncol Lett. 2021; 22(5):808.

PMID: 34630715 PMC: 8488329. DOI: 10.3892/ol.2021.13069.

Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.

Yang D, Wang W, Zhang Q, Pan H, Huang Y, Zhang J World J Gastroenterol. 2021; 27(17):2025-2038.

PMID: 34007137 PMC: 8108039. DOI: 10.3748/wjg.v27.i17.2025.

References

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T . Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2012; 58(3):495-501. DOI: 10.1016/j.jhep.2012.10.017. View

Han Y, Zhao J, Ma L, Yin J, Chang W, Zhang H . Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011; 17(38):4258-70. PMC: 3214700. DOI: 10.3748/wjg.v17.i38.4258. View

Tornesello M, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro F . Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013; 102(2):74-83. DOI: 10.1016/j.ygeno.2013.04.001. View

Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T . Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Genomics. 2013; 101(4):238-48. DOI: 10.1016/j.ygeno.2013.02.007. View

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao Y . Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401-16. PMC: 3899457. DOI: 10.2188/jea.je20100190. View

Aspinall E, Hawkins G, Fraser A, Hutchinson S, Goldberg D . Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond). 2011; 61(8):531-40. DOI: 10.1093/occmed/kqr136. View

Sahasrabuddhe V, Gunja M, Graubard B, Trabert B, Schwartz L, Park Y . Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012; 104(23):1808-14. PMC: 3514167. DOI: 10.1093/jnci/djs452. View

Lee D, Chung Y, Lee S, Kim S, Lee Y, Kim K . Effect of response to interferon-α therapy on the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B. Dig Dis. 2012; 30(6):568-73. DOI: 10.1159/000343068. View

. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1999; 351(9115):1535-9. View

10.

Du Y, Su T, Ding Y, Cao G . Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012; 12(10 HCC):e6031. PMC: 3500771. DOI: 10.5812/hepatmon.6031. View

11.

Aghemo A, Colombo M . Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol. 2012; 35(1):111-20. DOI: 10.1007/s00281-012-0330-z. View

12.

Yuen M, Seto W, Chow D, Tsui K, Wong D, Ngai V . Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2008; 12(8):1295-303. View

13.

Wong G, Chan H, Mak C, Lee S, Ip Z, Lam A . Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013; 58(5):1537-47. DOI: 10.1002/hep.26301. View

14.

Tinkle C, Haas-Kogan D . Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012; 6:207-19. PMC: 3421475. DOI: 10.2147/BTT.S23907. View

15.

Lavanchy D . Viral hepatitis: global goals for vaccination. J Clin Virol. 2012; 55(4):296-302. DOI: 10.1016/j.jcv.2012.08.022. View

16.

Lin H, Chen Y, Hsu W, Yang C, Kao C, Tsai T . Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila). 2012; 5(7):952-62. DOI: 10.1158/1940-6207.CAPR-12-0001. View

17.

Zemel R, Issachar A, Tur-Kaspa R . The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2011; 15(2):261-79, vii-x. DOI: 10.1016/j.cld.2011.03.001. View

18.

Fung J, Lai C, Seto W, Yuen M . Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011; 66(12):2715-25. DOI: 10.1093/jac/dkr388. View

19.

Lee M, Yang H, Liu J, Batrla-Utermann R, Jen C, Iloeje U . Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013; 58(2):546-54. DOI: 10.1002/hep.26385. View

20.

Kwon H, Lok A . Does antiviral therapy prevent hepatocellular carcinoma?. Antivir Ther. 2011; 16(6):787-95. DOI: 10.3851/IMP1895. View